Back to NUVB Overview
NYQ · Valuation Lab
NUVB
Nuvation Bio Inc.
Last$6.37
Market cap2.2B
EV/EBITDA-12.8x
Intrinsic value
$1.98
MoS -221.5% · Overvalued
Assuming 15.0% FCF margin and 10.0% Y1–5 growth.
Upside to price
EV (DCF)371.3M
Terminal share49%
Expected IV$2.03
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 49% of EV
PV of stage FCFs190M
PV of terminal value181.2M
Enterprise value371.3M
Net cash / (debt)316.7M
Equity value688M
Intrinsic value / share$1.98
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 157.4M | 23.6M | 21.2M | 90.0% |
| Y2 | 173.1M | 26M | 21M | 80.9% |
| Y3 | 190.4M | 28.6M | 20.8M | 72.8% |
| Y4 | 209.4M | 31.4M | 20.6M | 65.5% |
| Y5 | 230.4M | 34.6M | 20.4M | 58.9% |
| Y6 | 241.9M | 36.3M | 19.2M | 53.0% |
| Y7 | 254M | 38.1M | 18.2M | 47.7% |
| Y8 | 266.7M | 40M | 17.2M | 42.9% |
| Y9 | 280M | 42M | 16.2M | 38.6% |
| Y10 | 294M | 44.1M | 15.3M | 34.7% |
| Terminal | — | — | 181.2M | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.